drugset / Trial / NCT07643155
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of the study is to determine the effect of mild, moderate, and severe hepatic impairment on the PK of total treprostinil palmitil (TP) and treprostinil (TRE) following a single dose of 80 micrograms (μg) TPIP, when compared to normal hepatic function.
Timeline
- Start
- 2026-06-10
- Primary completion
- 2027-02-07
- Completion
- 2027-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Treprostinil Palmitil | Small molecule | 80 ug | Inhaled |
Indications
No indication recorded.